These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 16986231

  • 21. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
    Bissessor N, White H.
    Vasc Health Risk Manag; 2007; 3(4):425-30. PubMed ID: 17969373
    [Abstract] [Full Text] [Related]

  • 22. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 23. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 15; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 24. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C, Croce G, Desideri G.
    Adv Ther; 2008 Apr 15; 25(4):300-20. PubMed ID: 18449492
    [Abstract] [Full Text] [Related]

  • 25. Valsartan after myocardial infarction.
    Güleç S.
    Anadolu Kardiyol Derg; 2014 Dec 15; 14 Suppl 2():S9-13. PubMed ID: 25604205
    [Abstract] [Full Text] [Related]

  • 26. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D.
    Acta Med Croatica; 2004 Dec 15; 58(2):129-34. PubMed ID: 15208798
    [Abstract] [Full Text] [Related]

  • 27. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
    Nickenig G, Ostergren J, Struijker-Boudier H.
    J Renin Angiotensin Aldosterone Syst; 2006 Jun 15; 7 Suppl 1():S1-7. PubMed ID: 16969748
    [Abstract] [Full Text] [Related]

  • 28. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
    Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, Velazquez EJ, Maggioni AP, Califf RM, Swedberg K, Kober L, Belenkov Y, Varshavsky S, Pfeffer MA, Solomon SD, VALsartan In Acute myocardial iNfarcTion (VALIANT) Trial Investigators.
    Am Heart J; 2010 Jul 15; 160(1):145-51. PubMed ID: 20598985
    [Abstract] [Full Text] [Related]

  • 29. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun 15; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 30. Valsartan, captopril, or both in myocardial infarction.
    McAnulty JH.
    N Engl J Med; 2004 Feb 26; 350(9):943-5; author reply 943-5. PubMed ID: 14985495
    [No Abstract] [Full Text] [Related]

  • 31. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX, Ye X, Lee KY, Dupclay L, Plauschinat C.
    Clin Ther; 2008 Feb 26; 30 Pt 2():2217-27. PubMed ID: 19281916
    [Abstract] [Full Text] [Related]

  • 32. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z, Armaly Z, Nakhoul F, Hoffman A.
    Harefuah; 2008 Jun 26; 147(6):536-42, 573. PubMed ID: 18693632
    [Abstract] [Full Text] [Related]

  • 33. Renin-angiotensin system modulation: the weight of evidence.
    Brown B, Hall AS.
    Am J Hypertens; 2005 Sep 26; 18(9 Pt 2):127S-133S. PubMed ID: 16125049
    [Abstract] [Full Text] [Related]

  • 34. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
    MMW Fortschr Med; 2003 Dec 04; 145(49):18-9. PubMed ID: 14963986
    [No Abstract] [Full Text] [Related]

  • 35. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction.
    Sciarretta S, Paneni F, Palano F, Chin D, Tocci G, Rubattu S, Volpe M.
    Clin Sci (Lond); 2009 Mar 04; 116(6):467-77. PubMed ID: 19200056
    [Abstract] [Full Text] [Related]

  • 36. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R, Palmer BF.
    Am J Nephrol; 2008 Mar 04; 28(3):372-80. PubMed ID: 18073461
    [Abstract] [Full Text] [Related]

  • 37. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M.
    Am J Cardiol; 2007 Aug 06; 100(3A):38J-44J. PubMed ID: 17666197
    [Abstract] [Full Text] [Related]

  • 38. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
    Weber MA.
    J Renin Angiotensin Aldosterone Syst; 2003 Jun 06; 4(2):62-73. PubMed ID: 12806587
    [Abstract] [Full Text] [Related]

  • 39. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA.
    Am Heart J; 2000 Jan 06; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [Abstract] [Full Text] [Related]

  • 40. Blockade of the renin-angiotensin system. Effect on mortality in patients with left ventricular systolic dysfunction.
    Pitt B.
    Cardiol Clin; 1994 Feb 06; 12(1):101-14. PubMed ID: 8181019
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.